CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(04): 360-363
DOI: 10.1055/s-0041-1736680
Drug Review

Selinexor—A Drug Review

Hridya Jayamohanan
1   Department of Medical Oncology; Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
Vaibhav Venniyoor
2   Department of Internal Medicine, Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
,
1   Department of Medical Oncology; Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
› Author Affiliations

Abstract

Selinexor developed by Karyopharm Therapeutics is the first orally available small-molecule inhibitor of exportin-1 (XPO1). XPO-1 is a protein transporter responsible for the export of macromolecules such as tumor suppressor proteins and oncoprotein mRNAs from the nucleus to the cytoplasm; its inhibition results in blocking of multiple oncogenic pathways. Overexpression of XPO1 is seen in multiple myeloma and various other malignancies and is a poor prognostic marker. Pivotal positive trials have resulted in the approval of selinexor for use in refractory or relapsed diffuse large B cell lymphoma and multiple myeloma. In this review, we briefly cover the drug development, mechanism of action, indications, and toxicities of the drug, and the major pivotal trials.



Publication History

Article published online:
26 November 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India